FDA Oncology Announcements

EZH inhibitor × Lymphoid × Clear all

2 Announcements

FDA granted accelerated approval to tazemetostat for follicular lymphoma

Drug: TAZVERIK (tazemetostat) · EZH inhibitor
Condition: Lymphoid

FDA granted accelerated approval to tazemetostat for follicular lymphoma

Drug: TAZVERIK (tazemetostat) · EZH inhibitor
Condition: Lymphoid